Ionis Pharmaceuticals, Inc. (BMV:IONS)

Market Cap	209.73B +89.3%
Revenue (ttm)	16.99B +33.8%
Net Income	-6.87B
EPS	-42.91
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8
Average Volume	785
Open	1,150.00
Previous Close	1,100.00
Day's Range	1,150.00 - 1,150.00
52-Week Range	619.00 - 1,180.00
Beta	n/a
RSI	63.61
Earnings Date	Apr 29, 2026

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 1,402
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: IONS

Financial Performance

In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.

Financial numbers in USD